Impulse Dynamics raises $80m to commercialize Optimizer Smart System

Impulse Dynamics, a US medical device company, has secured $80.25 million in a Series D financing round led by medical technology investor Amzak Health Investors for the commercialization of its Optimizer Smart System for heart failure.

Optimizer Smart System is an implantable device which has been approved by the US Food and Drug Administration (FDA) to deliver cardiac contractility modulation therapy for the treatment of chronic heart failure and for strengthening the heart and help it beat with more force.

Simos Kedikoglou – Impulse Dynamics CEO said: “We are extremely pleased that our new strategic and financial investors recognize the significant potential of cardiac contractility modulation, or CCM therapy, with the Optimizer Smart.

“We look forward to accelerating the ramp-up of our commercial operations, particularly in the U.S. where we are just entering the market thanks to our two recent FDA approvals and CMS Transitional Pass-through payment approval, to make this potential a reality for physicians and their patients.”

The series D financing round also included the participation of Wellington Management, Acorn Biosciences, Kennedy Lewis Investment Management, and Minth Holdings, Zoll Medical, Abiomed, and an undisclosed corporate investor.

Impulse Dynamics said that CCM therapy with the Optimizer Smart System can relieve symptoms and improve the quality of life in Class III heart failure patients.

The CCM therapy works by transferring non-excitatory electrical pulses to the heart cells through the Optimizer Smart System to improve the heart’s systolic contraction.

Rich Gumer – managing director of Kennedy Lewis Investment Management said: “With CCM, Impulse Dynamics has developed a very important new therapy for a large and growing patient population who until now have had no real treatment alternatives.

“Our additional investment will help the company deliver a positive impact on a much larger scale – improving patient outcomes and generating significant savings to the healthcare system.”

Related posts

• Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure (0)